MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on May 5, 2025. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement on April 14, 2025, for a private placement with the following terms:
- Total Gross Proceeds: Approximately $1.08 million.
- Investor Component: Sale of 633,333 shares of Common Stock and warrants to purchase 633,333 shares at $1.50 per share (approx. $950,000).
- Director Component: Sale of 86,667 shares of Common Stock and warrants to purchase 86,667 shares at $1.50 per share (approx. $130,000).
- Warrant Terms: Exercise price of $2.05 per share; exercisable commencing one year after issuance; six-year term.
- Use of Proceeds: Funding the starting cost for Part C of the Phase II trial THIO-101 and working capital.
The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period, as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Unusual Items
On May 5, 2025, the Company issued a corrective press release to amend the initial exercise date and term of the warrants purchased in the private placement. The corrected terms state that warrants are exercisable commencing one year following issuance with a six-year term. The securities are being issued as restricted securities under Rule 144 without registration rights.
Guidance, Outlook, and Risks
Management intends to utilize the net proceeds to advance clinical development, specifically the THIO-101 Phase II trial. The closing of the transaction is expected on February 26, 2025, subject to customary closing conditions. The securities were sold in reliance on exemptions from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the final closing date of the private placement, which was expected to be February 26, 2025.
- Confirm the corrected warrant exercise terms (1-year lock-up, 6-year term, $2.05 strike price) as detailed in the corrective press release.
- Monitor the allocation of proceeds toward the THIO-101 Phase II Part C trial.
- Note that the securities issued are restricted and do not carry registration rights.